Precision Medicine
-
A preview of the INVEST Precision Medicine conference June 9-11
The conference highlights the intersections of technology and life sciences through the prism of precision medicine. The topics at the conference span pediatric innovation, how tech companies are addressing clinical trial challenges, supply chain management, and more.
-
Prometheus Bio’s IPO raises $190M for inflammatory bowel disease R&D
Prometheus Biosciences is taking a precision medicine approach to developing drugs and diagnostics for inflammatory bowel disease. The IPO cash will fund support its pipeline of IBD drug candidates for specific patient subpopulations.
-
How are healthcare organizations shifting to digital documents?
In order to gain insight into how organizations are thinking about digitizing medical documents and the strategy behind those decisions, we’re conducting a brief survey of the MedCity News audience and will publish a report based on this survey’s findings.
-
Amgen’s $1.9B Five Prime deal adds to cancer drug pipeline and Asia strategy
The acquisition brings Amgen a novel Phase 3-ready drug for gastric cancers. For Five Prime Therapeutics, the deal is a lifeline following a series of clinical and financial setbacks that left much of the biotech’s fortunes resting on its lead antibody drug.
-
How digital health impacts the development and adoption of cancer immunotherapies
In an interview, BrightInsight Co-founder and CEO Kal Patel, MD, offered a preview of the report, The Role of Digital Health in Immuno-oncology Therapy Development and Adoption.
-
How Tempus’ corporate counsel views healthcare innovation: A Q&A with Maggie Huston
In a wide-ranging interview, Maggie Huston, associate general counsel for precision medicine company Tempus, discusses how to balance innovation with safety as the FDA grapples with AI/ML and new, more complex technology, as well how her company quickly reacted to Covid-19.
-
Armed with $270M in capital, Scorpion Therapeutics aims to broaden the reach of precision oncology
Founded in 2020, Scorpion is agnostic about the potential therapies and targets it will explore with what it describes as its drug-hunting engine. But the company is hoping to unveil its first drug candidate this year.
-
Special Reports, Sponsored Post
A look at the diagnostics chapter of precision medicine
More than 80% of representatives of health systems have established genomic data management strategies or plan to do so within the next couple of years.
-
Getting the right data to doctors is next hurdle for precision medicine
The future of precision medicine will come only as quickly as doctors can pick out clinically useful information from the genetic data being gathered on their patients.
-
MedCity News Spotlight: How CancerIQ is advancing precision medicine
As part of our conferences and to augment panel discussions and presentations, we are launching MedCity News: Spotlight to use video to tell the story of important companies, executives and healthcare initiatives.
-
Bristol Myers Squibb SVP Ho Sung Cho highlights pioneering work with protein degradation in support of drug development
In a podcast with MedCity News, Cho talked about the company’s profile in the San Diego life science ecosystem, the need to fail fast and frequently in the early stages of drug development and the work BMS is doing to combat Covid-19.
-
StartUPDATES: New developments from healthcare startups
Read news from healthcare startups Outcomes4Me, Specifica, Segmed, and more.
-
Navigating the challenge of covering breakthrough therapies at MedCity INVEST Precision Medicine
A discussion on the different models healthcare stakeholders are developing to cover the cost of costly therapies will be just one of the compelling conversations at the virtual conference from December 9-11. Register today!
-
Mark your calendars for our virtual INVEST Precision Medicine conference, December 9-11
Here’s a preview of some of the panel discussions at INVEST Precision Medicine, including diagnostics, investment trends, and building a bioinnovation hub.
-
The precision medicine conference you don’t want to miss
The summit gathers directors through the C-suite from across life science and healthcare sectors to discuss new developments in precision medicine, investment trends, and how health IT, diagnostics and biopharma technology are being used to improve outcomes.
-
Foundation Medicine to launch liquid biopsy companion diagnostic following FDA approval
The company announced Wednesday the FDA approval of its liquid biopsy test, the second to win an agency nod in less than a month, saying it would launch the product on Friday. The FDA acquired the first ever liquid biopsy companion diagnostic, Guardant Health’s Guardant360 CDx, on Aug. 10.
-
CancerIQ raises $4.8M Series A funding round for cancer precision health technology
The Chicago-based startup company plans to use the funding to further growth of its product offering and integration with EHRs and genetic testing partners.
Promoted
How Presbyterian Is Using Digital Health Tools to Address Pandemic Challenges
Timing is everything. In the case of Presbyterian Healthcare Services, its adoption of the Bright.MD platform in 2017 to facilitate telehealth appointments was fortuitous. Read now to learn more.
